Cargando…

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrestha, Bimmi, Brien, James D., Sukupolvi-Petty, Soila, Austin, S. Kyle, Edeling, Melissa A., Kim, Taekyung, O'Brien, Katie M., Nelson, Christopher A., Johnson, Syd, Fremont, Daved H., Diamond, Michael S.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848552/ https://www.ncbi.nlm.nih.gov/pubmed/20369024 http://dx.doi.org/10.1371/journal.ppat.1000823

Ejemplares similares

Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope
por: Austin, S. Kyle, et al.
Publicado: (2012)

Potent Dengue Virus Neutralization by a Therapeutic Antibody with Low Monovalent Affinity Requires Bivalent Engagement
por: Edeling, Melissa A., et al.
Publicado: (2014)

Therapeutic Efficacy of Antibodies Lacking FcγR against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies
por: Williams, Katherine L., et al.
Publicado: (2013)

Correction: Therapeutic Efficacy of Antibodies Lacking Fc. Receptor Binding against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies
por: Williams, Katherine L., et al.
Publicado: (2013)

Structural basis of West Nile virus neutralization by a therapeutic antibody
por: Nybakken, Grant E., et al.
Publicado: (2005)

The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein
por: Smith, Scott A., et al.
Publicado: (2013)

Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus
por: Pal, Pankaj, et al.
Publicado: (2013)

The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies
por: Earnest, James T., et al.
Publicado: (2021)

Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus)
por: Azami, Nor Azila Muhammad, et al.
Publicado: (2018)

Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge
por: Zhao, Haiyan, et al.
Publicado: (2019)

A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes
por: Thompson, Bruce S., et al.
Publicado: (2009)

Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge
por: Kafai, Natasha M., et al.
Publicado: (2022)

In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection
por: de Alwis, Ruklanthi, et al.
Publicado: (2011)

Correction: In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection
por: de Alwis, Ruklanthi, et al.
Publicado: (2011)

Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus
por: Fernandez, Estefania, et al.
Publicado: (2018)

Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity
por: Earnest, James T., et al.
Publicado: (2019)

Capturing a Flavivirus Pre-Fusion Intermediate
por: Kaufmann, Bärbel, et al.
Publicado: (2009)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis
por: A. Dowd, Kimberly, et al.
Publicado: (2023)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura, et al.
Publicado: (2021)

A molecular understanding of alphavirus entry
por: Holmes, Autumn C., et al.
Publicado: (2020)

Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection
por: Pinto, Amelia K., et al.
Publicado: (2015)

Optimized heterologous transfection of viable adult organotypic brain slices using an enhanced gene gun
por: Arsenault, Jason, et al.
Publicado: (2013)

ACTION ON FIBROBLASTS OF EXTRACTS OF HOMOLOGOUS AND HETEROLOGOUS TISSUES
por: Carrel, Alexis, et al.
Publicado: (1923)

μ-Opioid receptor desensitization: homologous or heterologous?
por: Llorente, Javier, et al.
Publicado: (2012)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection
por: Auerswald, Heidi, et al.
Publicado: (2021)

Structure and Intracellular Targeting of the SARS-Coronavirus Orf7a Accessory Protein
por: Nelson, Christopher A., et al.
Publicado: (2005)

Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice
por: Chiuppesi, Flavia, et al.
Publicado: (2017)

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
por: Bekliz, Meriem, et al.
Publicado: (2022)

Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification
por: Balsitis, Scott J., et al.
Publicado: (2010)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022)

Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses
por: Tai, Wanbo, et al.
Publicado: (2018)

THE CATABOLISM OF HOMOLOGOUS AND HETEROLOGOUS 7S GAMMA GLOBULIN FRAGMENTS
por: Spiegelberg, Hans L., et al.
Publicado: (1965)

Stimulation of homologous recombination in plants expressing heterologous recombinases
por: Barakate, Abdellah, et al.
Publicado: (2020)

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
por: Mayr, Florian B., et al.
Publicado: (2022)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice
por: Salazar, Vanessa, et al.
Publicado: (2019)

Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography
por: Fox, Julie M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ositei4iimhs9hait23888ld93